The Optimal Plan To Utilize For CCI-779 Disclosed

Because the outcome phase always followed the decision phase and we wanted to assess regions uniquely involved during the outcome phase we controlled for the carryover effect of the BOLD response during the decision phase onto the outcome phase by exclusively masking the outcome contrasts with the decision contrast at p?OPHN1 model that included the negative outcome low-risk contrasts from the control and ketanserin groups together with the frequency of low-risk choices as covariates. The low-risk contrast images were kept separate for 5/7 and 6/7 odds. CCI-779 concentration However, as a few subjects lacked the 6/7 low-risk negative outcome event we controlled for a possible bias in subject contributions to the data by verifying the results in a separate model where the 5/7 and 6/7 low-risk events were pooled together. The significance of the linear relationship between BOLD response and choice behavior was assessed individually for the control and ketanserin sessions using linear regression models implemented in SPM. To control for possible non-specific effects of the drug's administration protocol and indirect effects of drug we rerun all 2nd level models with the control session substituted by the citalopram session. We considered clusters to be significant at p?=?0.05 after Family-Wise Error (FWE) correction for multiple non-independent www.selleckchem.com/products/ulixertinib-bvd-523-vrt752271.html comparisons applying a cluster-extent threshold of p?